Study of Beta-Blocker Treatment and Risk Factors in Patients With Idiopathic Ventricular Fibrillation After Cardiac Arrest

What this Trial Is About

Researchers are studying people who have survived a cardiac arrest with no clear cause, specifically focusing on those with idiopathic ventricular fibrillation IVF. These patients face a risk of having another cardiac arrest, and while implantable cardioverter-defibrillators ICDs are commonly used to prevent recurrence, the best medical treatment and ways to identify high-risk patients are not well established. This research aims to evaluate the effect of beta-blocker treatment on reducing irregular heart rhythms and to explore new risk assessment methods using genetic, toxicological, and advanced ECG data, along with assessing quality of life in these patients. The study compares two groups of patients one receiving beta-blocker treatment and one receiving no medication. The beta-blocker group will be given either a non-selective beta-blocker such as Propranolol Retard 80 mg daily or Nadolol 40 mg daily, or a selective beta-blocker like Atenolol 25 mg daily, Bisoprolol 2.5 mg daily, or Metoprolol 50 mg daily. Standard care is provided to all participants, and the study is randomized and single-blinded. Participants will be observed for up to three years after discharge, with the primary outcome being the first appropriate ICD therapy or the three-year mark. Quality of life will be assessed at three months and one year. Researchers will also collect data on genetic and toxicological profiles and analyze ECG patterns using machine learning to improve risk prediction. The study began in May 2018 and plans to continue until December 2035, offering long-term monitoring and evaluation of these patients health and treatment impacts.

MEdical Treatment in Idiopathic Ventricular Fibrillation Patients